Highlights from the 42nd annual meeting of the American Society of Clinical Oncology: Atlanta, GA, USA, 2 - 6 June 2006

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 16, 2006, Pages 2309-2318

  Puglisi, Fabio ^a   Andreetta, Claudia ^a   Fasola, Gianpiero ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Breast cancer; Chemotherapy; Colorectal cancer; Hormonal therapy; Myeloma; Non small cell lung cancer; Renal cancer; Targeted therapy

Indexed keywords

ANIMAL; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; HUMAN; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; METASTASIS; MULTIPLE MYELOMA; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III; COLORECTAL NEOPLASMS; HUMANS; KIDNEY NEOPLASMS; MULTIPLE MYELOMA; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 39049186328     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.16.2309     Document Type: Conference Paper

References (22)

1. VOGEL VG, COSTANTINO JP, WICKERHAM DL et al.: Effect of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. The National Surgical Adjuvant Breast and Bowel Project (NSABP). JAMA (2006) 295:2727-2741. •• A landmark study of chemoprevention for breast cancer. (Pubitemid 43920726)
2. GANZ A, LAND SR, WICKERHAM DL et al.: The study of tamoxifen and raloxifene (STAR): initial findings from the NSABP P-2 breast cancer prevention study. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA561.
3. FISHER B, COSTANTINO JP, WICKERHAM DL et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. (1998) 90:1371-1388. •• A landmark study of chemoprevention for breast cancer. (Pubitemid 28439961)
4. COOMBES RC, PARIDAENS R, JASSEM J et al.: First mature analysis of the Intergroup Exemestane Study. the Intergroup Exemestane Study (IES). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA527. • Update analysis of a randomised clinical trial on hormonal therapy in postmenopausal patients with breast cancer.
5. KAUFMANN M, JONAT W, HILFRICH J et al.: Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. The German Adjuvant Breast Cancer Group. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):547.
6. BIANCO AR, DE MATTEIS A, MANZIONE L et al.: Taxit216 Study Group: Sequential Epirubicin-Docetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter Phase III trial. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA520.
7. CROWN JP, FRANCIS P, DI LEO A et al.: Docetaxel (T) given concurrently with or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa), in comparison with non-T adjRx: First results of the BIG 2-98 Trial at 5 years median follow-up (MFU). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA519.
8. LUECK H, MINCKWITZ GV, DU BOIS A et al.: Epirubicin/paclitaxel (EP) versus capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre Phase III study of the AGO breast cancer study group. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):517.
9. FORBES JF, KENNEDY J, PIENKOWSKY T et al. : BCIRG 007: randomized Phase III trial of trastuzumab plus docetaxel with or without carboplatin first line in HER2 positive metastatic breast cancer (MBC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA516.
10. CARRATO A, KOEHNE C, BEDENNE L et al.: Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. For the AIO/CAO, FFCD, TTD, EORTC. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3563.
11. SCHMOLL HJ, TABERNERO J, NOWACKY M et al.: Final safety findings from a randomized Phase III trial of capecitabine + oxaliplatin (XELOX) versus bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3569.
12. FUCHS C, MARSHALL J, MITCHELL E et al.: A randomized trial of first-line irinotecan/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3506.
13. HOCHSTER HS, HART LL, RAMANATHAN RK, HAINSWORTH JD, HEDRICK EE, CHILDS BH: Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006) 3510.
14. VENOOK A, NIEDZWIECKI D, HOLLIS D et al.: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) ± cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3509.
15. MAINDRAULT-GOEBEL F, LLEDO G, CHIBAUDEL B et al.: OPTIMOX2, a large randomized Phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3504.
16. LA BIANCA R, FLORIANI I, CORTESI E et al.: Italian Group for the Study of Digestive Tract Cancer. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):3505.
17. PIGNON JP, TRIBODET H, SCAGLIOTTI GV et al.: A pooled analysis of five randomized clinical trials including 4,584 patients. The Collaborative Group Lung Adjuvant Cisplatin Evaluation (LACE). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):7008. • A pooled analysis of five randomised clinical trials of adjuvant chemotherapy for non-small cell lung cancer.
18. STRAUSS GM, HERNDON JE, MADDAUS MA et al.: Update of Cancer and Leukemia Group B (CALGB) protocol 9633. The CALGB, Radiation Therapy Oncology Group: Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):7007.
19. ARDIZZONI A, TISEO M, BONI L et al.: CISCA (cisplatin versus carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):7011. •• A meta-analysis of individual patient data on platin-based therapy for metastatic non-small cell lung cancer.
20. MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-á) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC) J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA3. •• A randomised clinical trial showing a survival benefit with the multitargeted tyrosine kinase inhibitor sunitinib in metastatic renal cell carcinoma.
21. HUDES G, CARDUCCI M, TOMCZAK P et al.: A Phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):LBA4. •• A randomised clinical trial showing a survival benefit with the inhibitor of mTOR kinase temsirolimus in metastatic renal cell carcinoma.
22. FACON T, MARY J, HAROUSSEAU J et al.: Superiority of melphalan-prednisone (MP) + thalidomide (THAL) over MP and autologous stem cell transplantation in the treatment of newly diagnosed elderly patients with multiple myeloma. J. Clin. Oncol. 2006 ASCO Annual Meeting Proceedings Part I. Vol.24, No. 18S (June 20 Suppl.) (2006):1. •• A Phase III trial demonstrating that the addition of thalidomide to standard chemotherapy prolongs the life of elderly patients with multiple myeloma. These results support the adoption of this regimen as a new standard of care in this patient population.